Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …

Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer
compounds that are widely used in the treatment of hematologic malignancies and solid …

Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …

Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …

PURPOSE Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell
lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells …

Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical
outcomes. Our understanding of its molecular makeup continues to improve risk …

Polatuzumab vedotin (PV) is an antibody–drug conjugate targeting CD79b that is approved
for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse …

In the phase 3 POLARIX study in previously untreated diffuse large B-cell lymphoma,
polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and …

Genetic testing has been applied for decades in clinical routine diagnostics of hematological
malignancies to improve disease (sub) classification, prognostication, patient management …

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy
worldwide, comprising approximately 30% of all lymphomas. Currently, 50% to 60% of …